chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient received a booster vaccination for his meningococcal too early. Confirmed with CDC that no harm should be to come to patient.
pt broke out in hives by Thursday PM worsening till Saturday MA then diminishing gradually until Tuesday AM went to MD on Friday PM the prescribed DPH;as of 5PM Tuesday the 9DEC has not had a dose of DPH but is free of hives for 24hr;
ACUTE ST ELEVATION MI, INFERIOR WALL 3/18/2022 --  RECURRENCE OF SAME SYMPTOMS
Patient received vaccine at 5:30pm and presented back to the pharmacy at 5:50pm after shopping. She stated that initially after receiving the vaccine that her upper arm and face felt tingling and different. She said that the tingling slowly started to go away and become less intense but that it still felt different. Upon questioning she did not feel like it was an allergic reaction, that her breathing was affected, or that she had any itching. She also stated that the tingling had almost went away and that it had not spread to anywhere else in her body. I told her to make sure to keep an eye on it and to follow up with me the next day to make sure it had resolved. I called the patient at 7pm on 9/6/15 to make sure the patient was ok and she stated that the tingling had stopped and she no longer had any side effects. I told her to keep a close eye on it and seek emergency medical attention if the tingling came back at all especially in the next two weeks since it could be an adverse reaction from the vaccine called Guillain-Barre syndrome.
Information has been received from a registered nurse (RN) concerning a 4-month-old female with no medical history or allergies who on 10-Oct-2006 was vaccinated PO with the second dose of Rotateq vaccine (human-bovine) (lot#655174/0848F). Concomitant therapy included ranitidine HCl (ZANTAC). The RN reported that on 10-Oct-2006, while receiving the second dose of Rotateq vaccine (human-bovine), the patient threw up and only received half (1.0 ml) of the recommended dose. Unspecified medical attention was sought. No laboratory/diagnostic tests were performed. On 10-Oct-2006, the patient recovered.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 08Oct2021 at 13:00 as dose 2, single (Batch/Lot number: unknown) at the age of 56 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "High blood pressure" (unspecified if ongoing); "prediabetes" (unspecified if ongoing); "Hives from high dose anti inflammatory meds and some antibiotics" (unspecified if ongoing); "Hives from high dose anti inflammatory meds and some antibiotics" (unspecified if ongoing); "Hives from high dose anti inflammatory meds and some antibiotics" (unspecified if ongoing). Concomitant medication(s) included: HYDROCHLOROTHIAZIDE; LISINOPRIL. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19 (Paxlovid treatment start date:18Aug2022 treatment stop date:23Aug2022).  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Fainting episode; Arm soreness; A spontaneous report was received from a Consumer concerning a 55-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events fainting episode, arm soreness.  The patient's medical history was not provided. Concomitant medications reported were Tysabri for drug use for unknown indication.  On 26 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot batch: 042L20A) intramuscularly for prophylaxis of COVID-19 infection.  On 26 Jan 2021, the patient experienced the events arm soreness. On 27 Jan 2021, the patient experienced fainting episode.  No treatment medication was provided.  Action taken with mRNA-1273 in response to the events was not reported.   On 27 Jan 2021, the outcome of events fainting episode was resolved. The outcome of events arm soreness was not reported.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the events, a causal relationship cannot be excluded.
chest congestion; severe cough; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 71 year-old patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 26Jul2021 (Lot number: FA7485) at the age of 71 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "'otoro' hysterectomy", start date: 1978 (unspecified if ongoing); "Hypothyroid" (unspecified if ongoing); "allergic to iodine" (unspecified if ongoing); "allergic" (unspecified if ongoing), notes: I am allergic to a lot of things (further clarifications unknown). Concomitant medication(s) included: SYNTHROID taken for hypothyroidism, start date: 1979 (ongoing); DELESTROGEN taken for hysterectomy (ongoing). The following information was reported: RESPIRATORY TRACT CONGESTION (non-serious) with onset 11Aug2021, outcome "recovered" (Aug2021), described as "chest congestion"; COUGH (non-serious) with onset 11Aug2021, outcome "recovered" (Aug2021), described as "severe cough".  Additional information: The concomitant medications included Delestrogen and Synthroid which the patient was taking that for almost 50 years. The patient was vaccinated at on 26Jul2021 and on 11Aug2021, 12Aug2021 and 13Aug2021 developed chest congestion with severe cough, but they subsided. Prior vaccination (Within 4 weeks) was none.  No follow-up attempts are possible. No further information is expected.
Woke up the next day with a headache. By noon, terrible chills started and by 4pm, fever of 101.2F and had to go to bed.
dizziness; weakness; heart is acting up; cannot swallow; difficulty on breathing; difficulty on walking; legs are hurting /  toes are hurting; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness), ASTHENIA (weakness), PALPITATIONS (heart is acting up), DYSPHAGIA (cannot swallow) and DYSPNOEA (difficulty on breathing) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 25-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jul-2021, the patient experienced DIZZINESS (dizziness), ASTHENIA (weakness), PALPITATIONS (heart is acting up), DYSPHAGIA (cannot swallow), DYSPNOEA (difficulty on breathing), GAIT DISTURBANCE (difficulty on walking), PAIN IN EXTREMITY (legs are hurting /  toes are hurting) and MYALGIA (sore arm). At the time of the report, DIZZINESS (dizziness), ASTHENIA (weakness), PALPITATIONS (heart is acting up), DYSPHAGIA (cannot swallow), DYSPNOEA (difficulty on breathing), GAIT DISTURBANCE (difficulty on walking), PAIN IN EXTREMITY (legs are hurting /  toes are hurting) and MYALGIA (sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication was not provided. Treatment information was not provided. Patient states that is upset because wasn't told that the vaccine is an experimental drug, and may be poisoning us and doesn't want to receive the second dose.   Reporter did not allow further contact
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 21-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021 at 11:09 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 03-Apr-2021 at 11:09 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 21.99 for dose administered on 03-Apr-2021.  No concomitant and treatment medications were reported.  Batch number 030B21A underwent temperature excursion on 03-Apr-2021 with temperature 34 degrees Fahrenheit from 09:00 AM. This vial was moved to fridge on 30-Mar-2021 and beyond use date for the vial was reported as 29-Apr-2021. Product moved to clinic on 03-Apr-2021.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic. It was reported that each time a vial was put into a cooler, sometimes there was a period of time of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour. The vial was not in a frozen state at the time of vaccine administration. After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.   This case was linked to MOD-2022-566976 (Patient Link).
This is a spontaneous report received from contactable consumer or other non-HCP (patient). A 68-year-old female patient received the 1st dose of BNT162B2 (Comirnaty, batch/lot# EL3302), at the age of 68, intramuscularly, right arm, on Jan 22, 2021, at 10:00, single dose, for COVID-19 immunisation. The patient has no medical history or concomitant medications. The patient reported chills and headache (some chills with 1st dose during the night with a headache, went away after 24 hours), onset Jan 22, 2021, with outcome of recovered (Jan 23, 2021). No therapeutic measures taken as a result of chills and headache. Additional information: No prior vaccinations (within 4 weeks). No tests reported. No follow-up attempts possible. No further information expected.
Information has been received from a registered nurse concerning a 7 year old male who was vaccinated with Varivax on approximately 23-AUG-2006. Within a minute after varicella administration, the patient experienced sneezing, swollen eyes, itchy throat and hives. The patient was seen by the physician on 30-AUG-2006 and most of the patient's symptoms were gone. No laboratory tests were performed. Additional information has been requested.
Patient received vaccine at 1345 and developed mild throat tightening, lip tingling at 1400 patient states similar symptoms that she developed to her first dose on 3/17 pt did not require medication after first dose- per pt report.  Pt was administered 50 mg Benadryl PO at 1440 due to possible slight worsening/ not improving  pt was sent top the ER at 1500 due to no improvement, possible slight improvement in symptoms, per pt report.
A few minutes after receiving his vaccinations and as I was finishing up freezing his wart on his hand, patient passed out. Fortunately, I was still close to him when it happened and I was able to catch him so he didn't injure himself. I layed him down and he came to within a few seconds. Pulse ox was placed on him and ranged from 96-98 with HR in the 80's. After a few minutes, he felt well enough to sit up. He was given a cup of water and goldfish which he tolerated well.
fever of 104.5 x 3 days, shrill crying, diarrhea & vomiting x 3 days; called MD several times told to cont APAP & observe pt closely;
1-2 days after the first vaccine (10/24/21) my daughter states she started feeling depressed and had increased anxiety. On 11/15/21, one day after the 2nd vaccination (11/14/21 -second vaccine)she was taken to the ER at the local Hospital for a psych evaluation , having thoughts of wanting to kill /harm herself.   It wasn?t until afterwards that we placed the common denominator of events as to being the Covid vaccine.
Area where the shot was administered feels warm; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Area where the shot was administered feels warm) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 18-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-May-2021, the patient experienced VACCINATION SITE WARMTH (Area where the shot was administered feels warm). At the time of the report, VACCINATION SITE WARMTH (Area where the shot was administered feels warm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.
Pt developed a stiffness and pain in the shoulder and neck of the left arm (the arm were the vaccine was delivered) with no explainable other reason.  The pain has continued for the last 6 days and according to the patient has not gotten better.
This spontaneous report was received from an approximately 70 years old male nurse who was also the patient. The patient's concurrent condition included chronic obstructive pulmonary disease. The patient did not have concomitant medications or drug reactions/allergies. Approximately in 2008 (reported as 10 years ago), the patient was vaccinated with a dose of pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) (dose, route, lot # and expiration date were not reported) for prophylaxis. Approximately in 2014 (reported as 4 years ago), the patient was vaccinated with another dose of pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) (dose, route, lot # and expiration date were not reported) for prophylaxis. On an unspecified date in 2016, the patient was operated on left upper lobe for non-small lung carcinoma. Then on an unspecified date, the patient was treated with cisplatin and another unspecified chemotherapy medication. On an unspecified date in 2017, a Positron Emission Tomography (PET) showed no active cancer and chemotherapy medications were terminated. On an unspecified date in 2018, the patient had tested and 90 % of expression for Programmed Death-ligand 1 (PD-L1) was found. On an unspecified date in March 2018, lesions in right lobe (lung cancer metastatic) were found with metastatic lesions in mediastinum and right clavicular. On 21-MAY-2018, the patient started therapy with KEYTRUDA (dose, frequency, lot # and expiration date were not reported) for routine vaccination. The patient did not seek medical attention. Additionally, the patient also reported that his spouse got influenza A, after getting an unspecified flu shot. No further information was provided. The outcome of non-small cell lung cancer and lung cancer metastatic was unknown. The reporter did not provide a causality assessment between the events and pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown). Upon internal review, the events non-small cell lung cancer and lung cancer metastatic were considered to be medically significant.
Seen evening 1/3/10 - left eye felt like something was in it - watered for 1/2 hr. I fell asleep. When I awoke on 1/4/10 - unable to close left eye or use muscles on that side of face - primary care diagnosed Bell's Palsy 1/4/10. Still Improving.
Initial and follow-up information has been received from a nurse concerning a 20 year old female patient who on 12-MAR-2007 was vaccinated with a first dose of GARDASIL vaccine (yeast) (lot number, injection site and route not reported). On 27-DEC-2007 the patient was vaccinated with a second dose of GARDASIL vaccine (yeast) (lot number, injection site and route not reported). On 13-AUG-2008 the patient was vaccinated with a third dose of GARDASIL vaccine (yeast) (lot number 0151X) in the deltoid (injection route not reported). No adverse symptoms. Additional information is not expected.
sniffles; post-nasal drip; nausea; fever; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (sniffles), NASAL DISCOMFORT (post-nasal drip), NAUSEA (nausea) and PYREXIA (fever) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 11-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RHINORRHOEA (sniffles), NASAL DISCOMFORT (post-nasal drip), NAUSEA (nausea) and PYREXIA (fever). The patient was treated with PARACETAMOL (TYLENOL) ongoing since an unknown date at a dose of unk dosage form. At the time of the report, RHINORRHOEA (sniffles), NASAL DISCOMFORT (post-nasal drip), NAUSEA (nausea) and PYREXIA (fever) outcome was unknown.            Action taken with mRNA-1273 in response to the events was not Applicable. Concomitant product use was not provided by the reporter.    Most recent FOLLOW-UP information incorporated above includes: On 05-May-2021: Follow up was received on 05 may 2021 included no new information.
Given Td in EC for laceration of finger. Per patient reaction started after the injection. Reaction reported was pain at injection site, redness, swelling (approx 4-5 cm induration. Rx given in EC for Benadryl.
This spontaneous case reported by a consumer, describes the occurrence of contusion (bruise on her leg, below her knee), fatigue (tiredness) and headache in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 037A21B) for COVID-19 immunization. No medical history reported. On Mar 23, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On Apr 9, 2021, patient experienced contusion (bruise on her leg, below her knee). On an unknown date, patient experienced fatigue (tiredness) and headache. At the time of the report, contusion (bruise on her leg, below her knee): not resolved; and fatigue (tiredness) and headache outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. Concomitant product use, causality assessments and treatment information not provided.
The patient came by today (1/27/21) and reported that ever since receiving her flu vaccine on 9/28/20, she has had chronic soreness in her shoulder. Lately it has gotten worse and she has made and appointment with her doctor to assess.
Information was received from a registered nurse, who reported that on multiple unspecified dates, multiple unspecified patients were administered improperly stored LIQUID PEDVAXHIB (lot #M032150, expiration date 21-APR-2019) (dosage and route of administration not provided). No adverse effects reported. No additional information provided. Temperature/Time frame: > 46°F but < 77°F for 1.5 hours. Additional information has been requested.; Sender's Comments:  US-009507513-1702USA009271: US-009507513-1702USA012016: US-009507513-1702USA012014:
After my first dose I developed a bad cough with a lot of mucus. I have to keep clearing my throat constantly.  I am still dealing with this at this time. They kept telling me that it would go away, but it hasn't. They also told me not to eat after 6 in the evening, but that didn't work either. I have been taking Mucinex because I have so much mucus. It doesn't make it go away, it just helps me breathe a little better.
20AUG94 rt cheek very swollen-started to subside 21AUG94; 23AUG94 AM difficulty focusing eyes, afternoon-cramping abdo pains, aching of legs & diarrhea; aching of all joints; felt warm-no temp taken; 26AUG94 has tiredness & mild aching;
Severe allergic reaction 6 days after the shot.  My daily routine had not changed in any way, which is why this had to be a reaction to the shot.  Arm began severely itching followed by feet, other arm, legs, torso.  Treated with Benadryl and anti itch lotion. Lasted about 18 hours.  3 doses of Benadryl.  Also, the first night I did run a fever that broke in a couple of hours.  These were the only reactions I have experienced.
Fever. Rash. Injection site rash. From initial information received on 06/Aug/2003 from a physician, regarding an adverse event occurring in the US, it was reported that a 7 month old male patient received his third dose of DAPTACEL, lot number C1386AA, given in the left thigh on 24/Jul/2003. In the evening of the same day, the patient developed a 101.2 fever, lasting for 48 hours and a rd rash at the injection site. The following day, 25/Jul/2003, the rash became generalized over the patient's entire body, no itching was reported. The patient was seen by a physician on an unspecified date. Reportedly, the rash is still persisting.
No adverse events.  CDC advised on 4/21/2023 around 1:00pm to give ALL recipients the Moderna Bivalent vaccine and did not provide any additional information regarding dose or which vial to give, until after the vaccine was already given.
I simply began hearing a loud "white noise" 24hrs x7day.  This occurred within a week of the first shot of the vaccine.  the sound is in my head, not my ears.   I went to my primary physician, who checked my ears and cleaned them of some wax.  she has referred me for evaluation with an audiologist and ENT specialist